These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25407396)

  • 21. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein.
    Sugikawa E; Tsunoda S; Nakanishi N; Ohashi M
    Anticancer Res; 2001; 21(4A):2671-5. PubMed ID: 11724337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy.
    Ahire V; Das D; Mishra KP; Kulkarni GR; Ackland L
    J Environ Pathol Toxicol Oncol; 2016; 35(4):355-364. PubMed ID: 27992315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological rescue of mutant p53 conformation and function.
    Foster BA; Coffey HA; Morin MJ; Rastinejad F
    Science; 1999 Dec; 286(5449):2507-10. PubMed ID: 10617466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening.
    Abbasi M; Sadeghi-Aliabadi H; Hassanzadeh F; Amanlou M
    J Mol Graph Model; 2015 Sep; 61():186-95. PubMed ID: 26277488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tumor suppressor gene p53 and molecular targeting therapy].
    Takimoto R; Niitsu Y
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1309-13. PubMed ID: 15446548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.
    Rehman A; Chahal MS; Tang X; Bruce JE; Pommier Y; Daoud SS
    Breast Cancer Res; 2005; 7(5):R765-74. PubMed ID: 16168122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virtual screening using covalent docking to find activators for G245S mutant p53.
    Omar SI; Lepre MG; Morbiducci U; Deriu MA; Tuszynski JA
    PLoS One; 2018; 13(9):e0200769. PubMed ID: 30192754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.
    Maurici D; Monti P; Campomenosi P; North S; Frebourg T; Fronza G; Hainaut P
    Oncogene; 2001 Jun; 20(27):3533-40. PubMed ID: 11429700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
    Bykov VJ; Issaeva N; Shilov A; Hultcrantz M; Pugacheva E; Chumakov P; Bergman J; Wiman KG; Selivanova G
    Nat Med; 2002 Mar; 8(3):282-8. PubMed ID: 11875500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding.
    Kaar JL; Basse N; Joerger AC; Stephens E; Rutherford TJ; Fersht AR
    Protein Sci; 2010 Dec; 19(12):2267-78. PubMed ID: 20878668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53.
    Joerger AC; Bauer MR; Wilcken R; Baud MGJ; Harbrecht H; Exner TE; Boeckler FM; Spencer J; Fersht AR
    Structure; 2015 Dec; 23(12):2246-2255. PubMed ID: 26636255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study.
    Kamaraj B; Bogaerts A
    PLoS One; 2015; 10(8):e0134638. PubMed ID: 26244575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prima-1 and APR-246 in Cancer Therapy.
    Zatloukalová P; Galoczová M; Vojtěšek B
    Klin Onkol; 2018; 31(Suppl 2):71-76. PubMed ID: 31023027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor Effects of PRIMA-1 and PRIMA-1
    Menichini P; Monti P; Speciale A; Cutrona G; Matis S; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G
    Cells; 2021 Jan; 10(1):. PubMed ID: 33430525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Common cancer mutations R175H and R273H drive the p53 DNA-binding domain towards aggregation-prone conformations.
    Li L; Li X; Tang Y; Lao Z; Lei J; Wei G
    Phys Chem Chem Phys; 2020 May; 22(17):9225-9232. PubMed ID: 32307496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
    Weinmann L; Wischhusen J; Demma MJ; Naumann U; Roth P; Dasmahapatra B; Weller M
    Cell Death Differ; 2008 Apr; 15(4):718-29. PubMed ID: 18202704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells.
    Russo D; Ottaggio L; Penna I; Foggetti G; Fronza G; Inga A; Menichini P
    Biochem Biophys Res Commun; 2010 Nov; 402(2):345-50. PubMed ID: 20946886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An inverse docking approach for identifying new potential anti-cancer targets.
    Grinter SZ; Liang Y; Huang SY; Hyder SM; Zou X
    J Mol Graph Model; 2011 Apr; 29(6):795-9. PubMed ID: 21315634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
    Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
    Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrinsic Differences in Backbone Dynamics between Wild Type and DNA-Contact Mutants of the p53 DNA Binding Domain Revealed by Nuclear Magnetic Resonance Spectroscopy.
    Rasquinha JA; Bej A; Dutta S; Mukherjee S
    Biochemistry; 2017 Sep; 56(37):4962-4971. PubMed ID: 28836764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.